Changeflow GovPing Pharma & Drug Safety Novel Oral Cannabinoid CBD Formulations Patent ...
Routine Notice Added Final

Novel Oral Cannabinoid CBD Formulations Patent Application

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260097052A1 for novel oral CBD formulations by five inventors including Hardin Matthew Jackson et al. The application covers solid oral dosage forms comprising the non-psychoactive cannabinoid CBD and methods of manufacture for treating diseases.

What changed

USPTO published patent application US20260097052A1 for novel oral CBD formulations on April 9, 2026. The application covers solid oral dosage forms comprising non-psychoactive cannabinoid CBD, methods of manufacture, and use for treating diseases. Inventors include Hardin Matthew Jackson, Devin Douglas Machin, Jinhee Oh, Venkat Reddy Goskonda, and Andrew Jonathan Saich. The application was filed December 12, 2025 under application number 19418328.\n\nAffected parties including pharmaceutical manufacturers, drug developers, and CBD product companies should monitor this application for potential licensing opportunities or freedom-to-operate concerns. The patent scope covering CBD solid oral dosage forms may impact competitive positioning in the pharmaceutical CBD space.

What to do next

  1. Monitor for patent grant status
  2. Review application for freedom-to-operate analysis
  3. Assess licensing opportunities for CBD formulations

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

NOVEL ORAL CANNABINOID FORMULATIONS

Application US20260097052A1 Kind: A1 Apr 09, 2026

Inventors

Hardin Matthew Jackson, Devin Douglas Machin, Jinhee Oh, Venkat Reddy Goskonda, Andrew Jonathan Saich

Abstract

The present disclosure relates to novel pharmaceutical formulations, including solid oral dosage forms comprising the non-psychoactive cannabinoid cannabidiol (CBD). The disclosure further relates to methods of manufacture of the pharmaceutical formulations and the use of the formulations to treat diseases and conditions.

CPC Classifications

A61K 31/658 A61K 9/4858 A61K 9/4866

Filing Date

2025-12-12

Application No.

19418328

View original document →

Named provisions

Abstract Inventors CPC Classifications Filing Date

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097052A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Pharmaceutical research Drug development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!